Skip to main content
. Author manuscript; available in PMC: 2015 May 19.
Published in final edited form as: Neurosci Lett. 2014 Jun 2;575:96–100. doi: 10.1016/j.neulet.2014.05.047

Fig. 4.

Fig. 4

Targeting p-tau via immunization significantly reduces early AT8 immunoreactivity. The phosphorylated residues of tau that make up the AT8 epitope also represent some of the earliest modifications observed in tau pathogenesis. (A) Staining for phosphorylated residues Ser199 and Thr202 (AT8) show a large decreased in reactive at 7 days post-injection. (B) Statistical analysis of AT8 immunoreactivity, at post injection day 7, reveals a significant decrease in AT8 treated vs. control IgG treated sections (t-test, ***P < 0.0001, N = 7). Scale bar equals 250 µm.